Table 3B.
Role of CMR in patients with COVID-19 vaccine-induced myocarditis.100, 101, 102, 103, 104, 105, 106, 107, 108, 109
| Author | Total patients/Myocarditis | Type of vaccine/dose | Cardiac investigations | Major findings |
|---|---|---|---|---|
| Shiyovich et al. | 4/4 | Pfizer-BNT162b2/Booster | ECG changes, troponin elevation | Increased T1/T2 and LGE |
| Nunn et al. | 4/4 | 3 Pfizer BNT162b2,1 mRNA-1273/Primary | ECG changes, troponin & BNP elevation | Increased T1/T2 and LGE |
| Manfredi et al. | 6/6 | 4 Pfizer-BNT162b2,2 mRNA-1273/Primary | Elevated troponins, atrial tachycardia | Increased T2 and LGE |
| Montgomery et al. | 23/23 | 7 Pfizer-BNT162b2,16 mRNA-1273/Primary | ECG changes, troponin elevation & echo changes | Increased T1/T2 and LGE |
| Kim et al. | 7/4 | 2 Pfizer-BNT162b2,2 mRNA-1273/Primary | ECG changes, biomarker elevation & echo changes | Increased T1/T2 and LGE |
| Dickey et al. | 6/6 | 5 Pfizer-BNT162b2,1 mRNA-1273/Primary | ECG changes, biomarker elevation & echo changes | Increased T2 signal and LGE |
| Mansour et al. | 2/2 | mRNA-1273/Primary | ECG changes, biomarker elevation | Increased T1, T2 signal and LGE |
| Marshall et al. | 7/7 | Pfizer-BNT162b2/Primary | ECG changes, biomarker elevation | LGE |
| Rosner et al. | 7 /7 | 5 Pfizer-BNT162b2,1 mRNA-1273, 1 adenovirus vaccine)/Primary | ECG changes, biomarker elevation | LGE in all patients increased T2 signal intensity in 3 patients |
| Larson et al. | 8/8 | 5 Pfizer-BNT162b2, 3 mRNA-1273/Primary | ECG changes, biomarker elevation & echo changes | LGE in all patients, edema in 6 patients |